SEC Form 4 · accession 0000899243-18-031810
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leiv Lea
Officer — Chief Financial Officer
Period of report
Dec 21, 2018
Accepted (ET)
Dec 27, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2 | Dec 21, 2018 | P | 24,700 | $4.1461 | A | 24,700 | I | By IRA |
| Common Stock, $0.0001 par valueF3,F4 | holding | — | — | — | 149,206 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $4.13 to $4.17 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
- F2These shares are held by Leiv Lea IRA Contributory.
- F3A portion of these shares is subject to a right of repurchase held by the Issuer.
- F4These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.